CervoMed (CRVO)
Develops neflamapimod for age-related brain disorders.
Something off on this page? Send us feedback.
Develops neflamapimod, an investigational oral small molecule, for dementia with Lewy bodies and other age-related brain disorders. The clinical-stage business is organized around this single lead candidate, including manufacturing work intended to improve drug concentrations.
Develops neflamapimod, an investigational oral small molecule designed to cross the blood–brain barrier and selectively inhibit p38α. Its clinical programs span dementia with Lewy bodies, non-fluent variant primary progressive aphasia, recovery after ischemic stroke, and amyotrophic lateral sclerosis.
Operations are concentrated in the United States, with a small internal team supported by outside consultants and contractors. The company’s work centers on advancing a single lead candidate through clinical development rather than selling commercial products.
RewinD-LB’s randomized phase did not show significant differences on its primary or secondary outcomes. Subsequent exploratory work examined a newer drug batch after the company identified a drug-substance property and implemented a manufacturing improvement. Clinical results remain investigational rather than regulatory evidence of safety or efficacy.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 20, 2026 | Roth Capital | Target | Target: $9 | Target: $7 |
| May 18, 2026 | Roth Capital | Target | Target: $20 | Target: $9 |
| Nov 5, 2025 | H.C. Wainwright | Target | Target: — | Target: $25 |
| Nov 5, 2025 | HC Wainwright & Co. | Upgrade | ||
| Oct 17, 2025 | Roth Capital | Target | Target: $16 | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.9M · Total debt $0 · Total assets $26.0M · Shareholders' equity $23.0M
- Revenue
- $0
- Operating income
- −$6.7M
- Net income
- −$6.6M
No dividends on record.
| Institutions | 18.87% | 1.75M shares | |
|---|---|---|---|
| 37 holders · as of Jun 30, 2026 | |||
| Insiders | 40.40% | 3.74M shares | |
| 5 holders · as of Jun 15, 2026 | |||
| Strategic holders | 25.30% | 2.34M shares | |
| 2 holders · as of Aug 14, 2026 | |||
| Other | 15.43% | 1.43M shares | |
| remainder | |||
9.26M company shares as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (15.12M in the company's Sep 22, 2026 report, 9.26M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Joshua S. BogerInsiderdirector, 10 percent owner | 23.81% | 2.20M | filed Jun 15, 2026 |
Armistice Capital, LLCStrategic | 17.20% | 1.59M | filed Aug 14, 2026 |
John J. AlamInsiderdirector, 10 percent owner, officer: CEO & President | 16.16% | 1.50M | filed Nov 19, 2025 |
RA Capital Management, L.P.Institution | 11.09% | 1.03M | filed Aug 20, 2025 |
CVI Investments, Inc.Strategic | 8.10% | 750,000 | filed Jun 26, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | Joshua S. Boger | director, 10 percent owner: | +2,866,242 | $3.20 |
| Nov 17, 2025 | John J. Alam | director, 10 percent owner, officer: CEO & President | +21,600 | $8.46 |
| Nov 17, 2025 | William Robert Elder | officer: CFO, GC & Secretary | +1,000 | $8.45 |
| Nov 18, 2025 | William Robert Elder | officer: CFO, GC & Secretary | +2,500 | $8.32 |
| Nov 17, 2025 | Sylvie Gregoire | director, 10 percent owner: | +21,600 | $8.46 |
- Cognition Therapeutics
DLB-psychosis pipeline with a once-daily oral therapy
- Coya Therapeutics
FTD and ALS pipeline built around COYA 302
- Ionis Pharmaceuticals
Targeted FUS-ALS therapy in a Phase 3 study
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CervoMed | $2.43 | +0.83% | $22.3M | — | — | 69.2 | −99.7% |
| Cognition Therapeutics | $1.01 | +0.50% | $89.5M | — | — | — | — |
| Coya Therapeutics | $5.20 | +5.05% | $116.1M | — | — | 14.5 | +35.6% |
| Ionis Pharmaceuticals | $45.57 | +1.49% | $7.46B | — | — | 8.5 | −40.7% |
| Median | — | — | 11.5 | −2.6% |